title: Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.
abstract: OBJECTIVE
  HIV/hepatitis C virus (HCV) coinfection causes accelerated liver disease compared to HCV monoinfection, and only 30-60% of HIV/HCV-coinfected individuals respond to HCV therapy with pegylated interferon and ribavirin. There are currently no biomarkers that predict treatment response in these coinfected patients.
  
  
  METHODS
  We investigated whether there is an association between HCV treatment response and SNPs of apoptosis-related genes during HIV/HCV coinfection.
  
  
  METHODS
  Genomic DNA from 53 HIV/HCV-coinfected individuals was analyzed for 82 SNPs of 10 apoptosis-related genes.
  
  
  RESULTS
  We found that the presence of the rs4242392 SNP in tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), which encodes for tumor necrosis factor-related apoptosis-inducing ligand receptor 1, predicts poor outcome to HCV therapy, in HIV/HCV-co-infected patients [odds ratio 5.91 (95% confidence interval 1.63-21.38, P = 0.007)].
  
  
  CONCLUSIONS
  The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients.
authors.affiliation: Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Stacey A
authors.initials: SA
authors.lastname: Rizza
authors.forename: Nathan W
authors.initials: NW
authors.lastname: Cummins
authors.forename: David N
authors.initials: DN
authors.lastname: Rider
authors.forename: Sahar
authors.initials: S
authors.lastname: Saeed
authors.forename: Marina B
authors.initials: MB
authors.lastname: Klein
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Badley
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002170:Canada; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008107:Liver Diseases / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012367:RNA, Viral; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000235:genetics*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D053219:Receptors, Tumor Necrosis Factor, Member 25; D011994:Recombinant Proteins; D012254:Ribavirin
references.citation: J Hepatol. 2008 Oct;49(4):548-56
references.pmid: 18619701
references.citation: Cell Death Differ. 2001 Feb;8(2):113-26
references.pmid: 11313713
references.citation: J Neuroimmunol. 2005 Oct;167(1-2):170-4
references.pmid: 16040132
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: Medicina (Kaunas). 2008;44(7):510-20
references.pmid: 18695347
references.citation: Int J Epidemiol. 2010 Oct;39(5):1162-9
references.pmid: 19786463
references.citation: J Viral Hepat. 2007 Jul;14(7):468-77
references.pmid: 17576388
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):2002-5
references.pmid: 17035413
references.citation: Gastroenterology. 2010 May;138(5):1885-97
references.pmid: 20334827
references.citation: Blood. 2005 Nov 15;106(10):3524-31
references.pmid: 16046522
references.citation: J Viral Hepat. 2010 Apr;17(4):245-53
references.pmid: 19709361
references.citation: Blood. 1994 Aug 15;84(4):1020-3
references.pmid: 8049420
references.citation: AIDS. 2007 May 31;21(9):1073-89
references.pmid: 17502718
references.citation: Curr Mol Med. 2009 May;9(4):495-505
references.pmid: 19519406
references.citation: Gut. 2005 Nov;54(11):1590-6
references.pmid: 16227360
references.citation: N Engl J Med. 2004 Jul 29;351(5):438-50
references.pmid: 15282351
references.citation: Cancer Biomark. 2007;3(2):89-93
references.pmid: 17522430
references.citation: Clin Cancer Res. 2000 Feb;6(2):335-46
references.pmid: 10690508
references.citation: Clin Infect Dis. 2001 Aug 15;33(4):562-9
references.pmid: 11462196
references.citation: J Neuroimmunol. 2004 Apr;149(1-2):195-201
references.pmid: 15020080
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15903-8
references.pmid: 19717445
references.citation: J Transl Med. 2008 Aug 09;6:44
references.pmid: 18691426
references.citation: AIDS. 2003 May 2;17(7):1023-8
references.pmid: 12700452
references.citation: J Virol. 2001 Nov;75(22):11128-36
references.pmid: 11602752
references.citation: J Infect Dis. 2006 Apr 1;193(7):945-53
references.pmid: 16518756
references.citation: J Infect Dis. 2006 Oct 15;194(8):1098-107
references.pmid: 16991084
references.citation: Nat Genet. 2009 Oct;41(10):1105-9
references.pmid: 19749757